The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight ...

Mind your investment horizon.

AbbVie (NYSE: ABBV) is a top healthcare stock, but it isn't trading like one of late. This year, it's down 11%, and it has been underperforming the S&P 500, which is down only 4%. Investors have been ...

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the ...

AbbVie's revenue for the first quarter came in at $15 billion, 12.4% higher than the year-ago period. The company had ...

Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 Stocks to Buy on a Pullback. On April 20, 2026, Canaccord initiated coverage of AbbVie Inc. (NYSE:ABBV) with a Buy rating and a $262 price target on the shares ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...